- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00748709
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
An Open Label Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Tainan, Taiwan
- 1200.26.88603 Boehringer Ingelheim Investigational Site
-
Taipei, Taiwan
- 1200.26.88601 Boehringer Ingelheim Investigational Site
-
Tao-Yuan, Taiwan
- 1200.26.88602 Boehringer Ingelheim Investigational Site
-
-
-
-
California
-
Los Angeles, California, Verenigde Staten
- 1200.26.3 Boehringer Ingelheim Investigational Site
-
-
Colorado
-
Denver, Colorado, Verenigde Staten
- 1200.26.11 Boehringer Ingelheim Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten
- 1200.26.9 Boehringer Ingelheim Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten
- 1200.26.1 Boehringer Ingelheim Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten
- 1200.26.13 Boehringer Ingelheim Investigational Site
-
-
New York
-
Albany, New York, Verenigde Staten
- 1200.26.4 Boehringer Ingelheim Investigational Site
-
New York, New York, Verenigde Staten
- 1200.26.2 Boehringer Ingelheim Investigational Site
-
-
Ohio
-
Kettering, Ohio, Verenigde Staten
- 1200.26.7 Boehringer Ingelheim Investigational Site
-
-
Texas
-
Dallas, Texas, Verenigde Staten
- 1200.26.12 Boehringer Ingelheim Investigational Site
-
Tyler, Texas, Verenigde Staten
- 1200.26.8 Boehringer Ingelheim Investigational Site
-
-
Virginia
-
Norfolk, Virginia, Verenigde Staten
- 1200.26.6 Boehringer Ingelheim Investigational Site
-
-
Washington
-
Vancouver, Washington, Verenigde Staten
- 1200.26.10 Boehringer Ingelheim Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion criteria:
There are 2 Steps in the screening process:
Step 1 Inclusion criteria for pre-screening:
Histologically confirmed diagnosis of advanced cancer of one of the following four tumor type categories:
Category 1, Gastric, GE junction, or Esophageal cancer Category 2, Biliary or gallbladder cancer Category 3, TCC urothelial tract, and Category 4, Gynecological cancers
- Measurable disease by RECIST criteria.
- Willingness and ability to give written informed consents consistent with ICHGCP guidelines.
- Life expectancy of at least three (3) months.
- Eastern Cooperative Oncology Group performance score 0, 1 or 2.
- Age >18 years.
Step 2 Inclusion criteria for enrollment:
Patients who have tested positive for FISH and are considered candidate for this trial must meet all of the following inclusion criteria:
Histologically confirmed diagnosis of advanced cancer of one of the following four tumor type categories:
Category 1, Gastric, GE junction, or Esophageal cancer Category 2, Biliary or gallbladder cancer Category 3, TCC urothelial tract, and Category 4, Gynecological cancers
- Documented failure to respond or progression of underlying cancer after at least one line of prior chemotherapy.
- EGFR and/or HER2 gene amplification by FISH testing or patients with tumors that harbor known activating EGFR mutations.
- Measurable disease by RECIST criteria.
- Willingness and ability to give written informed consents consistent with ICH-GCP guidelines.
- Life expectancy of at least three (3) months.
- Eastern Cooperative Oncology Group performance score 0, 1 or 2.
- Age >18 years.
Exclusion criteria:
- Prior treatment with gefitinib, erlotinib, lapatinib and/or other EGFR TKIs.
- Treatment with cytotoxic anti-cancer-therapies or investigational drugs during the last four weeks prior to the first treatment with the trial drug. (a shorter duration may be considered for patients treated with oral, non cytotoxic drugs on an individual basis and upon discussion between the principal investigator and sponsor)
- Inability to take BIBW 2992 by mouth (BIBW 2992 may not be crushed or administered via Gastrostomy-tube)
- Chronic diarrhea or other gastrointestinal disorders that may interfere with the absorption of the trial drug.
- History of other malignancies unless free of disease for at least 3 years (except for appropriately treated superficial non-melanoma skin cancer and surgically cured cervical cancer in situ).
- History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomization.
- Resting left ventricular ejection fraction <50% OR below the institution's lower limit of normal (if the institutions lower limit is above 50%), measured by MUGA scan or echocardiogram.
- Active infectious disease
- Serious illness, concomitant non-oncological disease or mental problems considered by the investigator to be incompatible with participation in this trial.
- Active/symptomatic brain metastases. Patients with a history of treated brain metastases must have stable or normal brain MRI scan at screening and be at least three months post-radiation or surgery for brain metastasis.
- Absolute Neutrophil Count (ANC) less than 1,000/mm3.
- Platelet count less than 100,000/mm3.
- Hemoglobin Level less than 9.0 grams/dl.
- Total Bilirubin greater than 1.5 mg/dl; higher Total Bilirubin values may be acceptable for patients with known Gilbert¿s disease, approval by the PI and sponsor will be necessary.
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 times the upper limit of normal; or 5 times the upper limit of normal in patients with neoplastic liver involvement.
- Serum creatinine greater than 1.5 x upper limit of normal for the institution.
- Patients who are sexually active and unwilling to use simultaneously two medically acceptable method of contraception, one of which being a barrier type method such as condom.
- Pregnancy or breast-feeding.
- Patients unable to comply with the protocol
- Active alcohol and/or substance abuse.
- Continuation of therapy-related toxicities from prior anti cancer therapies, prior surgery, of CTCAE Grade >=2 at the time of the first administration of the trial drug.
- Patients with known pre-existing interstitial lung disease.
- Requirement for treatment with any of the prohibited concomitant medications: additional experimental anti-cancer treatment and/or standard chemotherapy, immunotherapy, hormone treatment or radiotherapy; P-gp inhibitors
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: BIBW 2992 (Afatinib)
BIBW 2992 (Afatinib) for patients FISH positive for/or harboring EGFR or HER2 Mutation
|
BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage of Participants With Objective Response (OR)
Tijdsspanne: Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks thereafter
|
OR is defined as the percentage of patients with complete response (CR) or partial response (PR) and was assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST 1.0).
|
Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks thereafter
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage of Participants With Clinical Benefit (CB)
Tijdsspanne: Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock
|
CB was defined as CR, PR or stable disease (SD) and was assessed according to RECIST 1.0 criteria.
|
Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock
|
Time to Objective Response (OR)
Tijdsspanne: Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock
|
The time to OR was the duration from the first treatment to the time when the measurement criteria for CR and/or PR were met according to RECIST 1.0 criteria.
|
Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock
|
Duration of OR
Tijdsspanne: Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock.
|
Duration of OR was measured from the time the criteria for CR or PR (whichever was documented first) were first met until the first date that progressive disease or death was objectively documented.
|
Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock.
|
Progression-free Survival (PFS)
Tijdsspanne: Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock.
|
PFS was defined as the time from the start of treatment to the occurrence of disease progression or death, whichever came first.
Disease progression was assessed according to RECIST 1.0 criteria as well as by the investigators assessment, progression date recorded from post trial follow up or start of new anticancer treatment.
|
Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock.
|
Patients With AEs Resulting in Dose Reduction or Treatment Discontinuation
Tijdsspanne: First administration of trial medication until 28 days after last administration of trial medication
|
Patients with adverse events (AEs) resulting in dose reduction or treatment discontinuation
|
First administration of trial medication until 28 days after last administration of trial medication
|
Maximum CTCAE Grade
Tijdsspanne: First administration of trial medication until 28 days after last administration of trial medication
|
Patients with AEs by maximum Common Terminology Criteria for Adverse Events (CTCAE) grade
|
First administration of trial medication until 28 days after last administration of trial medication
|
Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 15 (Cpre,ss,15) for Patients on 50mg on Day 15
Tijdsspanne: Day 15
|
Cpre,ss,15 represents the pre-dose concentration of afatinib in plasma at steady state on day 15 for patients on 50mg on day 15.
|
Day 15
|
Number of Patients With Diarrhea or Rash
Tijdsspanne: First administration of trial medication until 28 days after last administration of trial medication
|
Number of Patients with Diarrhea or Rash
|
First administration of trial medication until 28 days after last administration of trial medication
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1200.26
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op BIBW 2992 (Afatinib)
-
Centre Leon BerardBoehringer IngelheimVoltooidHoofd-hals plaveiselcelcarcinoomFrankrijk
-
Boehringer IngelheimVoltooidBorstneoplasmataVerenigde Staten, Verenigd Koninkrijk
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooidGlioomVerenigde Staten, Canada
-
Boehringer IngelheimVoltooidCarcinoom, niet-kleincellige longKorea, republiek van
-
Medical University of South CarolinaBoehringer IngelheimIngetrokkenLongkankerVerenigde Staten
-
Boehringer IngelheimVoltooid
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)BeëindigdHoofd-hals plaveiselcelcarcinoomVerenigde Staten
-
M.D. Anderson Cancer CenterBoehringer IngelheimBeëindigdLongkankerVerenigde Staten
-
Boehringer IngelheimVoltooid